Furthermore, CRC patients with high SEMA4C protein expression in the TMA-CRC cohort also showed poorer OS (P = 0.014) and tumor-free survival (TFS; P = 0.024) compared to those with low SEMA4C expression (Figure 3E, 3F). This evidence concerns the gene SEMA4C and neoplasm.